drugset
drugset / Trial / NCT06394518

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

NCT06394518 ↗

Phase 1 Completed 32 enrolled TenNor Therapeutics Limited
RandomizedSequentialDouble-blindTreatment

Summary

This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.

Timeline

Start
2022-07-07
Primary completion
2023-02-24
Completion
2023-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject RIFAQUIZINONE Small molecule 200 mg Intravenous
Subject RIFAQUIZINONE Small molecule 300 mg Intravenous
Subject RIFAQUIZINONE Small molecule 400 mg Intravenous

Indications

periprosthetic joint infection